All Videos

For decades, the power and potential of outsourcing has been viewed as a way for pharmaceutical companies to gain access to specialized domain expertise across geographic regions and achieve cost savings amidst a highly complex and diverse regulatory environment. In the face of dwindling drug pipelines, complex regulations and block-busters crossing their patent exclusivity, mature products offer a revenue stream for companies to sustain their bottom lines in a hyper-competitive global market.

Cell and gene therapies continue to expand rapidly, with an anticipated exponential growth over the next five years. This rapid growth has left an urgent need for industry scientists to gather and share lessons learned concerning bioanalytical, biomarker and regulatory strategies. This series provides insight from PPD Laboratories’ experts into a variety of cell and gene therapy (CGT) modalities in the bioanalytical community, with detailed discussions that leverage their experience with technologies and modalities within this CGT sphere.

Nanoform’s Eric Peter talks about what Nanoform showcased at AAPS 2021and what makes Nanoform’s particle engineering solutions unique.

Dr. Prasad Raje, CEO of LGM Pharma, explores the importance of investing in robust analytical testing services, how pharma companies can leverage contract analytical services to save on costs and reduce development times, and more.